DaVita stock just endured a 17% single day drop, yet the earnings story that triggered it looks far more measured. The company delivered adjusted earnings per share of US$4.02 in the quarter and reaffirmed full year adjusted earnings guidance around US$14.65. For a healthcare services stock that closed yesterday near US$228 and now trades around US$189, this is a sentiment shock focused less on an earnings miss and more on worries about long term margins and debt.

Is DaVita suddenly a 48% off value opportunity, or is this lower P/E simply the market pricing in softer growth and debt risk? Compare that gap yourself on the valuation analysis for DaVita

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$3,415.55m vs. US$3,379.53m…